The NOBLE study: A Phase 2 multi-center, randomized, double blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of T-817MA in patients with mild to moderate Alzheimer’s Disease
April 07, 2015
Steven Potkin, MD
UC Irvine Medical Center.
To evaluate a new treatment for people with mild to moderate Alzheimer’s disease.
Adults 55-85 years old with probable mild to moderate Alzheimer’s disease on Aricept or Exelon patch treatment for at least 6 months. Subjects must have a study partner with whom they have regular contact. Weight of no more than 220 pounds.
In-clinic visits every 4 weeks for 12 weeks and then every 6 weeks for 1 year.
Participation in this study may help to improve your condition, but it is also possible that your condition may not improve or could worsen. There is no guarantee that you will personally benefit by participating in this research study. Your participation in this study may help the investigators learn more about the safety and benefits of T-817 for Alzheimer’s disease to help other people who have a similar medical problem in the future.
$2500 for subject and $300 for study partner.